LEMAITRE VASCULAR INC LMAT 89.01
Health Care · NASDAQ · Data as of 2026-08-05
LEMAITRE VASCULAR INC (LMAT) has delivered +12.1% annualized revenue growth, +15.6% earnings growth, and +19.7% dividend growth over 10 years of data. Ranked #14 of 1968 stocks overall and #2 of 260 in the Health Care sector by Steady Score.
About LEMAITRE VASCULAR INC
Company Overview
LeMaitre Vascular develops, manufactures and markets medical devices and implants used mainly by vascular surgeons to treat disease outside the heart. Its portfolio includes biologic and synthetic vascular grafts, vascular and cardiac patches, embolectomy and occlusion catheters, carotid shunts, valvulotomes and anastomotic clips. The company also processes and cryopreserves human vascular tissue for implantation, serving hospitals in North America, Europe and Asia-Pacific.
Read more
Business Model & Revenue
Revenue is generated from sales of single-use devices, implants and processed human tissue used in vascular procedures. LeMaitre sells primarily through its own specialist sales representatives, who call directly on vascular surgeons and hospitals, while distributors cover additional countries. Product mix, procedure volumes, selling prices and geographic expansion drive sales. The company operates as one segment and supplements internally developed products with acquired product lines and technologies.
Key Facts & Market Position
LeMaitre concentrates on the relatively narrow field of peripheral vascular surgery rather than the broader medical-device market. About 95% of 2025 sales came from territories served by its direct sales organization, giving the company close contact with specialist users. Its range spans disposable instruments, permanent implants and preserved human tissue, which require different manufacturing and regulatory capabilities.